OR WAIT 15 SECS
A recent report from GlobalData, data and analytics company, forecasts the Opioid Use Disorder Market (OUD) to see substantial growth over the coming decade. The market will grow at a compound annual growth rate (CAGR) of 10.3% from $1.8 billion in 2017 to $4.8 billion in 2027.
According to GlobalData’s latest report, ‘Opioid Use Disorder (OUD): Opportunity Analysis and Forecasts to 2027’, the opioid epidemic in the US meant the region contributes 88.8% of sales to the global market, and the government is taking several steps to introduce policies which control the crisis. These policies, as well as the launch of four late stage pipeline agents, will be the key drivers of growth in the OUD market.
Current treatments are based around maintenance therapy with an opioid agonist, buprenorphine and methadone, or an opioid antagonist, naltrexone. In the case of an overdose, naloxone can be used as an acute rescue medication, and in some cases, it is used in combination with buprenorphine.